PROS1 and COVID-19: Figure 1B–G illustrates the approaches used to develop COVID-19 vaccines (approved for phase 3 clinical trials or already approved for use) based on the SARS-CoV-2 S protein and its fragments. Table 2 shows examples of some recombinant protein COVID-19 vaccines.